The results were extremely encouraging, surpassing expectations and solidifying the case for its use in providing a reliable supply of radium isotopes (i.e. Ra-224 and Ra-228) to the emerging alpha therapy market.
“The preliminary experiments were meant to validate performance assumptions related to the central component of our separation process. Not only did the experiments validate our assumptions, they exceeded them in many respects. The results give us great confidence as we head into full proof of concept experimentation. We are very thankful for the support of PNNL personnel with preliminary work and are looking forward to performing our next set of experiments with their team.” Commented Andy Edwards, Chief Technical Officer at RadTran LLC. Pacific Northwest National Laboratory, commissioned by RadTran, has completed a series of testing to demonstrate proof of concept for the RadTran IsoCap-AA process. These experiments evaluated the performance RadTran’s IsoCap-AA process for extraction reliability.
Pacific Northwest National Laboratory is a leader in radiochemistry experimentation and technology development. They serve as an ideal partner to perform remaining experimentation. Proof of concept experiments are scheduled to resume in February of 2019. Isocap-AA scalability demonstration will commence at PNNL following successful completion of proof of concept work.